AbCellera BiologicsABCL
Recorded

AbCellera Biologics Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration27 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Roger SongSenior Analyst

All right. Welcome everyone to Jefferies 2026 Global Healthcare Conference in London. My name is Roger Song, Senior Analyst, covers biotech in the U.S. It is my pleasure to have a fireside chat with AbCellera. We have CEO Carl Hansen with me.

Carl HansenCEO

Great to be here. Thanks, Roger.

Roger SongSenior Analyst

Excellent. Okay, Carl, a lot of excitement happened to your company. Can you give us the state of the art of AbCellera and why you are excited about 2027 and beyond?

Carl HansenCEO

Sure. First, thanks for having us. Just to set the stage, AbCellera is a biotech company in Vancouver. We are focused on making antibody therapeutics. We spent the first 10 years of the company building a platform that we now think is best in world, particularly for solving the really difficult challenges in antibody discovery. Good examples being antibodies that are functional against ion channels, against GPCRs, and increasingly some work in T-cell engagers. Much of that work was done through a partnership mode. We were essentially hired guns for biotech and big pharma. 2023, we decided to switch gears. We started to ramp down that business and have been focused on our internal portfolio, and just over the last year, had our first two programs enter the clinic. One of them was an OX40 ligand antibody that we got opportunistically.

Carl HansenCEO

It's read out well, but we've decided to pause it based on the class. The most exciting one is our lead asset, which is ABCL635. It's a first-in-class antibody antagonist of NK3R that is being developed for the non-hormonal treatment of hot flashes or vasomotor symptoms associated with both menopause and with androgen deprivation or hormone deprivation in cancer therapy. We just had our phase II readout in August, and basically, the data blew the doors off. We've got efficacy that is twice as good in frequency as the small molecules that are approved, four to five times as good in severity, a clean safety profile, and we are now getting ready to engage with the regulators and bring that into late-stage studies next year. We think we've got something that could really redefine the treatment of hot flashes from a non-hormonal perspective.

Roger SongSenior Analyst

Great. Not many times we can really double or triple, quadruple the standard of care on efficacy. Okay, so that four-week data absolutely knocked people's socks off. You do have another dataset coming early next year. That is a 12-week following the single dose, and then the four weeks for the second dose, and then placebo crossover. Maybe for this one, on the single dose A and the 12-week, how should we think about that data? I know it's single dose and a washout, and then when we see the data, what would be considered as to be good and then supportive?

Carl HansenCEO

Sure. Thanks for asking. Maybe I'll start just by describing the study, because it does create some confusion because it's a little bit unusual the way it was set up. What we did in phase II is a single dose, 600 milligrams given once, and that dose was intended to mimic what would be the steady state exposure or concentration of a once-monthly 300-milligram injection. Then we had a single four-week efficacy readout. This is severity and frequency of hot flashes. That's the data that we read out in August, and that is the only really important efficacy readout as part of this study. The study actually goes for 12 weeks, so the next eight weeks is about having a washout period. The antibody we've disclosed has a half-life of roughly 30 days, so we've got three total half-lives where the antibody's washing out.

Carl HansenCEO

Over that period, because of the nature of this pathway, you have a very tight temporal correlation between efficacy and target engagement. We're able to use the exposure response data on a patient-by-patient basis to build up a detailed model of exposure response for the target, and that is being brought forward to the FDA through a model-informed drug development program, which allows us to specify the phase III doses based on that. To sum it up, the four-week was the efficacy, the next eight-week is a washout. We haven't yet shown that data. We will be showing it early next year. As you mentioned, in addition to that, we'll be adding to that data disclosure the open-label extension where both the placebo arm and the active arm get another dose, another 600-milligram dose, followed by four-week data.

Carl HansenCEO

In terms of what looks good, we anticipate, and I think would be terrific to have data that is confirmatory of what we already saw at four weeks. We are expecting the efficacy to wane up to 12 weeks, then we dose again. We will get the first glimpse of two doses, which helps to inform on durability of response, which in this class has been very good, and also gives additional data to further de-risk anti-antibody responses, which we have not seen to date and we feel good about as well. As well as a first dose of the placebo arm, which is interesting because the placebo arm, there is quite a placebo response, which I attribute primarily to reversion to the mean. After that is washed out, you will get to dose it and see if that patient group goes to where it was before.

Carl HansenCEO

In terms of positivity, we want to maintain a super clean safety signal. We have seen no evidence of liver toxicity, which has been a problem for the small molecules, we think is due to metabolism. We haven't seen a gastrointestinal safety signal, which has also been an issue with some of the small molecules. We want to keep that clean. Then we would like to see efficacy that looks comparable to what it was before. Given the gap we have, we are optimistic that will be the case.

Roger SongSenior Analyst

Excellent. Just on the single dose, that is a washout period.

Roger SongSenior Analyst

Yeah. Any efficacy toward the later part, particularly for the eight, 10, particularly for the 12 weeks, any efficacy should be good.

Roger SongSenior Analyst

Investors should not over-interpret if the efficacy goes down, even below the oral. That is still the very acceptable profile.

Carl HansenCEO

Yeah, but if it turned out that the efficacy reverted to zero over that period, it would still be fine because that's not the intended dosing schedule. I think given what we've already seen, like over the four weeks, we saw rapid response. We got already to better than orals, or at least equal to orals in the first week, and it continued to get better through the four-week period. I think it's unlikely it'll rebound completely, but we do expect a degradation, and we're waiting to see what that looks like.

Roger SongSenior Analyst

Got it. All right. That's very clear. On the four-week endpoint, because you set a very high bar for yourself, right? It's not set by anybody, not your competitor, not the standard of care, not the clinically meaningful. What would be a still very good scenario if the four week is lower than what you saw before? Because comparable is fantastic. The validation and reaffirmation, that's very good. Let's say 50% or 75% higher than the standard of care, you will be still very, very happy about that?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day